Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial.

Weinrauch, Larry A; D'Elia, John A; Weir, Matthew R; Bunnapradist, Suphamai; Finn, Peter; Liu, Jiankang; Claggett, Brian; Monaco, Anthony P

Weinrauch, Larry A; D'Elia, John A; Weir, Matthew R; Bunnapradist, Suphamai; Finn, Peter; Liu, Jiankang; Claggett, Brian; Monaco, Anthony P.

Afiliación

Weinrauch LA; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
D'Elia JA; Kidney and Hypertension Section,Joslin Diabetes Center, Boston, MA.
Weir MR; Medicine and Surgery, Beth Israel Deaconess Medical Center, Boston MA.
Bunnapradist S; Harvard Medical School, Boston MA.
Finn P; Kidney and Hypertension Section,Joslin Diabetes Center, Boston, MA.
Liu J; Medicine and Surgery, Beth Israel Deaconess Medical Center, Boston MA.
Claggett B; Harvard Medical School, Boston MA.
Monaco AP; University of Maryland School of Medicine, Baltimore, MD.

Int J Nephrol Renovasc Dis ; 10: 233-242, 2017.

Article en En | MEDLINE | ID: mdl-28860838

Palabras clave

diabetes; immunomodulation; immunosuppression; kidney transplant

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Tipo de estudio: Clinical_trials / Risk_factors_studies Idioma: En Revista: Int J Nephrol Renovasc Dis Año: 2017 Tipo del documento: Article País de afiliación: Marruecos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google